Palatin Technologies Gross Profit 2006-2021 | PTN

Palatin Technologies gross profit from 2006 to 2021. Gross profit can be defined as the profit a company makes after deducting the variable costs directly associated with making and selling its products or providing its services.
Palatin Technologies Annual Gross Profit
(Millions of US $)
2020 $0
2019 $60
2018 $67
2017 $45
2016 $
2015 $13
2014 $
2013 $0
2012 $0
2011 $1
2010 $14
2009 $11
2008 $11
2007 $14
2006 $18
2005 $17
Palatin Technologies Quarterly Gross Profit
(Millions of US $)
2021-03-31 $0
2020-12-31 $-0
2020-09-30 $-0
2020-06-30
2020-03-31
2019-12-31 $0
2019-09-30 $0
2019-06-30 $60
2019-03-31
2018-12-31
2018-09-30 $0
2018-06-30 $21
2018-03-31 $9
2017-12-31 $11
2017-09-30 $27
2017-06-30 $34
2017-03-31 $11
2016-12-31
2016-09-30
2016-06-30
2016-03-31
2015-12-31
2015-09-30
2015-06-30
2015-03-31
2014-12-31 $8
2014-09-30 $5
2014-06-30
2014-03-31
2013-12-31
2013-09-30
2013-06-30
2013-03-31
2012-12-31 $0
2012-09-30 $0
2012-06-30 $0
2012-03-31 $0
2011-12-31 $0
2011-09-30 $0
2011-06-30 $0
2011-03-31 $0
2010-12-31 $1
2010-09-30 $0
2010-06-30 $1
2010-03-31 $3
2009-12-31 $7
2009-09-30 $4
2009-06-30 $4
2009-03-31 $5
2008-12-31 $1
2008-09-30 $1
2008-06-30 $1
2008-03-31 $1
2007-12-31 $1
2007-09-30 $9
2007-06-30 $3
2007-03-31 $3
2006-12-31 $4
2006-09-30 $5
2006-06-30 $5
2006-03-31 $5
2005-12-31 $3
2005-09-30 $5
2005-06-30 $6
2005-03-31 $3
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.105B $0.000B
Palatin Technologies, Inc is a development-stage medical technology companyinvolved in developing and commercializing products and technologies fordiagnostic imaging, cancer therapy and ethical drug development These developments are based on its proprietary monoclonal antibody radiolabeling and enabling peptide platform technologies.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $133.660B 8.90
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.482B 21.14
Biohaven Pharmaceutical Holding (BHVN) United States $8.764B 0.00
Emergent Biosolutions (EBS) United States $2.892B 6.98
Arcus Biosciences (RCUS) United States $2.573B 0.00
Myovant Sciences (MYOV) United Kingdom $2.051B 0.00
ADC Therapeutics SA (ADCT) Switzerland $2.021B 0.00
Zymeworks (ZYME) Canada $1.443B 0.00
Ambrx Biopharma (AMAM) United States $0.527B 0.00
SQZ Biotechnologies (SQZ) United States $0.417B 0.00
Enzo Biochem (ENZ) United States $0.172B 50.71